CLINICIAN'S ANALGESIC ARSENAL


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review presents the main stages in the formation of pain, the clinical classification of pain, and methods for its objective evaluation, which enable the selection of an effective therapeutic strategy. Particular attention is paid to the choice of drugs taking into account the comorbidity of the patient, as well as the analysis of data of studies on safety and efficacy of these medicines.

Full Text

Restricted Access

About the authors

A. S Mikhailova

V.A. Nasonova Research Institute of Rheumatology

Email: mikhaylovamail@ya.ru
PhD, Educator at the Department of Residency and Postgraduate Study

References

  1. Meizack R. Pain and the neuromatrix in the brain. J. Dental. Education 2001;65:1378-82.
  2. Резник Л.Б., Турушев М.А., Ерофеев С.А., Дзюба Г.Г. Локальная инъекционная терапия при повреждениях и заболеваниях опорно-двигательной системы. М., 2016. 126с.
  3. Боль. Руководство для врачей и студентов / Под ред. Яхно Н.Н. М., 2009. 302 с.
  4. Worldwide palliative care alliance (WPCA); World Health Organization 2015. www.who.int/nmh/ Globai_Atias_of_Pailiative_Care.pdf.
  5. Кукушкин М.Л. Общая патология боли. М.: Медицина, 2004. 144 с.
  6. Merskey H., Bogduk N. Classification of Chronic Pain: Descriptions of chronic pain syndromes and definitions of pain terms. Seattle: IASP Press, 1994. 2nd ed. P 164-222.
  7. Данилов А.Б., Давыдов О.С. Нейропатическая боль. М., 2007. 192 с.
  8. Турбина Л.Г., Гордеев С.А. Диагностика и лечение нейропатической боли. Учебное пособие. М., 2014. 20 с.
  9. van Koulil S., Effting M., Kraaimaat F.W., et al. Cognitive-behavioural therapies and exercise programmes for patients with fibromyalgia: state of the art and future directions. Ann. Rheumatic Dis. 2007;66:571-81.
  10. Astin J.A. Mind-body therapies for the management of pain. Clinical J. Pain 2004;20:27-32.
  11. Доступно по адресу: http://www.who.int/ cancer/palliative/painladder/en
  12. Pendleton A., et al. The epidemiology of clinical trials in knee osteoarthritis showing a large bias towards randomised controlled trials of oral nonsteroidal anti-inflammatory drugs (NSAIDs). Ann. Rheumatic Dis. 2000;59:936-44.
  13. Huskinsson E.C., Irani M., Murray F. A large prospective open-label, multi-centre SAMM study, comparing the safety of aceclofenac with diclofenac in patients with rheumatic disease. Eur. J. Rheumatol. Inflammat. 2000;17:1-7.
  14. Ревматология. Фармакотерапиябезошибок/Под ред. В.И. Мазурова, О.М. Лесняк. М., 2016. 527 с.
  15. Allegri M., Clark M.R., et al. Acute and chronic pain: where we are and where we have to go. Minerva Anestesiology. 2012;78(2):222-35.
  16. Schug S., Manopas A. Update on the role of non-opioids for postoperative pain treatment. Best Practice and Research Clinical Anaesthesiology. 2007;21(1):15-30.
  17. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;1:4-24.
  18. Camu F. The role of COX-2 inhibitors in pain modulation. Drug. 2003;63(suppl.):1-7.
  19. Mehta V., Johnston A., Cheung R., et al. Intravenous parecoxib rapidly leads to COX-2 inhibitory concentration of valdecoxib in the central nervous system. Clinical Pharmacol. Therapeutics. 2008;83(3):430-35.
  20. Watson M., Brookes S.T., Faulkner A., Kirwan J. Non-aspirin, non-steroidal and anti-inflammatory drugs for treating osteoarthritis of the knee. Cochrane Database Systematic Review. 2007. doi: 10.1002/14651858.
  21. Singh G., Triadafnoupulus G. Epidemiology of NSAID induced gastrointestinal complications. J. Rheumatol. 1999;26(suppl. 58).
  22. Castellsague J., Pisa F., Rosolen V., et al. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol. Drug Safety. 2013;22(4):365-75. doi: 10.1002/pds.3385.
  23. Bhatt D.L., Scheiman J., Abraham N.S., et al. ACCF/ACG/AHA Expert Consensus Document: Antiplatelets, NSAIDs, and GI Risk JACC. 2008;52(18):1502-17.
  24. Warner T., et al. Proceedings of the National academy of Sciences of the United States of America, PNAS. 1999;96:7563-68.
  25. Combe B., Swergold G., McLay J., et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinic trial (The MEDAL study). Rheumatology. 2009;48:425-32.
  26. Moore A., Makinson G., Li C. Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials. Arthritis Research Therapy. 2013;15(1):R6. Doi: 10.1186/ ar4134.
  27. Castellsague J, Riera-Guardia N, Calingaert B., et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and metaanalysis of observational studies (the SOS project). Drug Safety: An International J. Medical Toxicol. Drug Experience. 2012;35(12):1127-46.
  28. Assessment report for Non-Steroidal AntiInflammatory Drugs (NSAIDs) and cardiovascular risk EMA/696137/2012.
  29. FDA (2015) FDA strengthens warning of heart attack and stroke risk for non-steroidal antiinflammatory drugs. FDA's Consumer Updates page, 9 July. http://www.fda.gov/ForConsumers/ ConsumerUpdates/ucm453610.htm
  30. Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: ИМА-ПРЕСС, 2009. 167с.
  31. Бадокин В.В. Сложности выбора оптимального нестероидного противовоспалительного препарата: в фокусе мелоксискам. РМЖ. 2016;26:1772-76.
  32. Singh G., Fort J.G., et al. Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study. Am. J. Medicine. 2006;119(3):255-66.
  33. Asghar W., Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology. 2015;23(1):1-16. doi: 10.1007/s10787-014-0225-9.
  34. Секреты ревматологии / Под ред. Дж. У Стерлинга. Пер. с англ. / Под ред. О.М. Лесняк М., 2018. 760 с.
  35. Каратеев А.Е. Может ли амтолметил гуацил пригодиться в хирургической практике? Амбулаторная хирургия. Стационарозамещающие технологии. 2017:1-2(65-66):15-22.
  36. Garg A., Shoeb A., Moodahadu L.S., et al. Amtolmetin: A Reappraisal of NSAID with Gastroprotection. Arthritis, 2016;2016:7103705. doi: 10.1155/2016/7103705.
  37. Coruzzi G., Coppelli G., Spaggiari S., et al. Gastroprotective effects of amtolmetin guacyl: a new non-steroidal anti-inflammatory drug that activates inducible gastric nitric oxide synthase. Digestive and Liver Diseases. 2002; 34(6):403-10.
  38. Jajic'Z., Malaise M., Nekam K., et al. Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis. Clin. Experimental Rheumatol. 2005;23:809-18.
  39. Bertaccini G., Coruzzi G. Amtolmetin guacyl: a new antiinflammatory drug devoid of gastrolesive properties. Naunyn-Schmiedeberg's Archives Pharmacology. 1998;358:(Suppl. 1):R366.
  40. Marcolongo R., Frediani B., Biasi G., et al. A MetaAnalysis of the Tolerability of Amtolmetin Guacil, a Novel, Effective Nonsteroidal Anti-Inflammatory Drug, Compared with Established Agents. Clinical Drugs Investigation. 1999;17(2):89-96.
  41. Fransen M., McConnell S. Exercise for osteoarthritis of the knee: a Cochrane systematic review. Br. J. Sports Medicine. 2015;49(24):1554-57. doi: 10.1136/bjsports-2015-095424.
  42. Garcia-Hermoso A., Saavedra J.M., Escalante Y. Effects of exercise on functional aerobic capacity in adults with fibromyalgia syndrome. A systematic review of randomazid controlled trials. J. Back Musculosklet Rahabilitation. 2015;28 (4):609- 19. doi: 10.3233/BMR-140562.
  43. Chou R., Cote P., Randhawa K. The Global Spine Care Initiative: applying evidence-based guidelines on the non-invasive management of back and neck pain to low- and middle-income communities. Eur. Spine J. 2018. doi: 10.1007/s00586-017-5433-8.
  44. Moore R.A., Gay-Escoda C., Figueiredo R., et al. Dexketoprofen/tramadol: randomised doubleblind trial and confirmation of empirical theory of combination analgesics in acute pain. J. Headache Pain. 2015;16:541. doi: 10.1186/s10194-015-0541-5.
  45. Woolf C., Mannion R. Neuropathic pain: aetiology, symptoms, mechanisms and management. Lancet. 2001;357(suppl. 1):1959-64.
  46. Stillman M. Clinical approach to patients with neuropathic pain. Cleveland Clinical J. Medicine. 2006;73(8):726-39.
  47. Психиатрия. Национальное руководство / Под ред. Т.Б. Дмитриевой, В.Н. Краснова, Н.Г. Незнанова, В.Я. Семке, А.С. Тиганова. М., 2011. 1000 с.
  48. Brodie M.J., Kwan Р. Newer drugs for focal epilepsy in adults. Br. Med. J. 2012;344:e345.
  49. Власов П.Н., Наумова Г.И., Дрожжина Г.Р. Новые противоэпилептические препараты. Качественная клиническая практика. 2008;3:12-28.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies